Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy
Sandhya Sharma, Mae Woods, Naren Mehta, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 4, pp. e006267-e006267
Open Access | Times Cited: 9

Showing 9 citing articles:

The paths and challenges of “off-the-shelf” CAR-T cell therapy: An overview of clinical trials
Vahid Moradi, Azadeh Omidkhoda, Naser Ahmadbeigi
Biomedicine & Pharmacotherapy (2023) Vol. 169, pp. 115888-115888
Open Access | Times Cited: 23
Rejection resistant CD30.CAR-modified Epstein-Barr virus-specific T cells as an off-the-shelf platform for CD30+ lymphoma
David H. Quach, H.R. Ganesh, Yolanda D Briones, et al.
Deleted Journal (2024) Vol. 32, Iss. 2, pp. 200814-200814
Open Access | Times Cited: 4
Potential alternatives to αβ-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: A comprehensive review
Chaozhi Tang, Yuling Zhang
Pathology - Research and Practice (2024) Vol. 262, pp. 155518-155518
Closed Access | Times Cited: 3
Constitutive Interleukin-7 Cytokine Signaling Enhances the Persistence of Epstein–Barr Virus-Specific T-Cells
Sandhya Sharma, Tim Sauer, Bilal Omer, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 21, pp. 15806-15806
Open Access | Times Cited: 4
Cotargeting EBV lytic as well as latent cycle antigens increases T-cell potency against lymphoma
Sandhya Sharma, Naren Mehta, Tim Sauer, et al.
Blood Advances (2024) Vol. 8, Iss. 13, pp. 3360-3371
Open Access | Times Cited: 1
B7-H3–Targeting Chimeric Antigen Receptors Epstein-Barr Virus–specific T Cells Provides a Tumor Agnostic Off-The-Shelf Therapy Against B7-H3–positive Solid Tumors
Siok Ping Yeo, Lindsay Kua, Jin Wei Tan, et al.
Cancer Research Communications (2024) Vol. 4, Iss. 6, pp. 1410-1429
Open Access | Times Cited: 1
Stem cell memory EBV-specific T cells control EBV tumor growth and persist in vivo
Darya Palianina, Juliane Mietz, Claudia Stühler, et al.
Science Advances (2024) Vol. 10, Iss. 34
Open Access | Times Cited: 1
Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy
Pei Y. Teo, Youngrock Jung, David H. Quach, et al.
Cancer Immunology Research (2024) Vol. 12, Iss. 8, pp. 1108-1122
Closed Access
Reversing Immunosenescence with Senolytics to Enhance Tumor Immunotherapy
Niu Liu, Jiaying Wu, Enze Deng, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Page 1

Scroll to top